By Milt Freudenheim
N.Y. Times News Service
NEW YORK _ Profiting from pressures to get patients out of expensive hospital beds quickly, companies that provide intravenous nutrition and drugs in the home have been on a roll. Sales of these solled homefusion companies tripled in three years to $3.2 billion in 1991 and may reach $4 billion this year, analysts said.
But when healthre stocks began slipping early this year, some highying homefusion stocks were hit even harder. Many investors who thought the economy would pick up this year switched from health care to cyclical stocks like autos and chemicals.
Companies like Baxter International's …